131I-Metuximab
December 26, 2024
Manufacturer
Chengdu Huasun Technology Group (CIRC)
131I-Metuximab, marketed under the brand name Licartin, is a radiolabeled murine antibody initially developed by the Fourth Military Medical University. It has been commercialized by Chengdu Huasun Technology Group (previously Chengdu Taihe Health Technology and formerly known as Chengdu Huasun) in collaboration with the China Isotope & Radiation Corporation (CIRC).
Drug Description
This product can be regarded as a “me-too” radiolabeled analogue of Cetuximab, targeting CD147 (also referred to as Basigin, BSG, or extracellular matrix metalloproteinase inducer – EMMPRIN). CD147 plays a significant role in tumor progression and metastasis. The drug was launched exclusively in China in 2006.
Clinical Applications
131I-Metuximab is designed to treat liver cancer, particularly:
- Hepatocellular carcinoma (HCC): It specifically targets the HCC-associated antigen HAb18G/CD147.
- Primary liver cancer cases: Approved for use in patients where surgery is not an option or who have experienced a relapse of primary liver cancer or have advanced disease.
The drug has shown efficacy in cases where Transcatheter Arterial Chemoembolization (TACE) treatment is not viable or has proven ineffective.
Clinical Trials
A Phase IV clinical trial has been recently completed, further evaluating the drug’s safety and efficacy.
Availability and Pricing
Licartin (131I-Metuximab) is currently only available for medical use in China, and its distribution is limited to this market.
Competitive Landscape
131I-Metuximab primarily serves as an alternative to TACE, with no significant competitors directly addressing its specific clinical niche.
Global Development and Interest
Despite its potential, 131I-Metuximab has not garnered interest for development or commercialization outside of China. This lack of international interest leaves its global footprint minimal, though it remains a significant player within its domestic market.